Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
(Stockholm, 4 March 2022) Inhalation Sciences (ISAB) has received a new order worth 23 500 Euro from a returning customer - RISE, the Research Institute of Sweden, one of the country's leading research bodies. RISE is purchasing ISAB's Nebulizer Aerosol Generator, which enables precise dry powder-like aerosol to be generated from liquid solutions when mounted onto PreciseInhale®. RISE carries out a wide range of international research projects and collaborations, many funded by national and European public bodies.
The new order, worth 23 500 Euro, is for ISAB's Nebulizer Aerosol Generator which enables dry powder-like aerosol to be generated from liquid solutions, as well as powders, when mounted onto PreciseInhale®, which RISE already has in-house. With many biologic substances, including vaccines, in solution form, the Nebulizer Aerosol Generator significantly broadens the range of research offerings a research organization like RISE can provide.
The new order illustrates too how PreciseInhale® can be expanded as a system over time to meet the customer's growing needs and deliver significant returns on investment. With its versatile modular architecture PreciseInhale® aerosol generator can input substances from a wide range of sources (inhalers, nebulizers or dry powder) and then generate aerosol output to a wide range of in vitro, in vivo or ex vivo exposures - all with PreciseInhale's trademark high precision and low standard deviation data.
RISE: a high-potential, high-innovation client
RISE is a state-owned organization that carries out extensive research projects and collaborations both nationally and internationally including in the inhalation field - many funded by EU and government grants. The organization identifies innovative development within SMEs as a key goal and promotes collaboration on research between academia, industry and the public sector.
Matilda Bäckberg PhD, MSc, Project Leader at RISE: "We chose to complement our PreciseInhale® system with Inhalation Sciences' nebulizer module. RISE and ISAB have a common focus on developing this research area in order to offer relevant research services for inhalation studies in the preclinical phase. This purchase will enable us to increase our offer of services and get more in vivo projects in 2022".
ISAB CEO Manoush Masarrat: "We believe that our technology and the capabilities it provides could very well open new doors and offer new opportunities for further collaboration on larger projects moving forward. We are delighted to be collaborating again with a customer that shares such key values. This is an exciting and important development."
The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on March 4, 2022.